Login / Signup

Removing barriers to accessing medical cannabis for paediatric patients.

Richard J HuntsmanJesse ElliottEvan LewisCharlotte Moore-HepburnJane AlcornHolly MansellJuan P AppendinoRichard E BélangerScott CorleyBruce CrooksAnneMarie M DennyYaron FinkelsteinAllen FinleyRyan FungAndrea GilpinCatherine LitalienJulia JacobsTimothy F OberlanderAshley PalmJacob PalmMonika PolewiczDeclan QuinnS Rod RassekhAlexander RepetskiMichael J RiederAmy Robson-McKayBlair SeifertAlan ShackelfordHal SidenMichael SzafronGeert 't JongRégis VaillancourtLauren E Kelly
Published in: Paediatrics & child health (2023)
Medical cannabis (MC) may offer therapeutic benefits for children with complex neurological conditions and chronic diseases. In Canada, parents, and caregivers frequently report encountering barriers when accessing MC for their children. These include negative preconceived notions about risks and benefits, challenges connecting with a knowledgeable healthcare provider (HCP), the high cost of MC products, and navigating MC product shortages. In this manuscript, we explore several of these barriers and provide recommendations to decision-makers to enable a family-centered and evidence-based approach to MC medicine and research for children.
Keyphrases
  • healthcare
  • young adults
  • primary care
  • intensive care unit
  • emergency department
  • palliative care
  • ejection fraction
  • risk assessment
  • clinical practice
  • climate change
  • patient reported outcomes